Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by TedOwenson Jan 04, 2014 7:29pm
604 Views
Post# 22059062

RE:RE:RE:RE:RE:RE:Rumblings of third party counter deal for Black-Grey Fox

RE:RE:RE:RE:RE:RE:Rumblings of third party counter deal for Black-Grey Fox The exchange we are having on the merits of the Brigus - Primero dealings virtues are counterpart to looking at the big picture from different perspectives. The advantage for Primero is much more obvious than it is for Brigus in that the resource base at Black-Grey Fox is much better understood by Conway that it is by Dawe. This projects regional footprint is returning considerable levels of parallel evidence of a much larger system being in place to expand but most of it is almost completely surrounded by St. Andrew Goldfields holdings. Results pending from the St. Andrew workings along strike to the Grey Fox are going to reveal a much bigger story. While the deal may appear very appealing to the average retail investor, the commentary coming from this side is based on direct exposure on the exploration front. While the deal may appear lucrative in the short term, the long term picture is exponentially superior for Brigus over the medium to long if they remain independent towards a gold price return. The streams attached to the Black-Fox are problematic but the Grey-Fox outlook is much larger and has no gold stream attached. The long term debts attached to Brigus are a drop in the hat compared to the valuation of the projects intrinsic long term fundamentals and shareholders will be in a superior position with St. Andrew than they would be with Primero on a regional exploration play the size that is in place with St. Andrew. It may not look as lucrative to start but Brigus shareholders should hold tight and wait out the storm.....We know this project better than Brigus does from past experience and it would be vital that shareholders consider what would be in their best interests within 6 months time.
Bullboard Posts